Saturday, November 21, 2026

Less Than Two Hours Before The NASDAQ Open, FibroGen Is Down By 7%

ViaNews Editorial Team

January 2, 2024

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Less Than Two Hours Before The NASDAQ Open, FibroGen Is Down By 7%

(VIANEWS) - The NASDAQ opens in less than two hours and FibroGen's pre-market value is already 7.31% down.

FibroGen's last close was $0.89, 96.55% below its 52-week high of $25.69.

The last session, NASDAQ ended with FibroGen (FGEN) falling 2.49% to $0.89. NASDAQ fell 0.56% to $15,011.35, after two consecutive sessions in a row of losses, on what was a somewhat negative trend exchanging session.

About FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.

Moving Average

FibroGen's value is way above its 50-day moving average of $0.58 and way under its 200-day moving average of $6.96.

Earnings Before Interest, Taxes, Depreciation, and Amortization

FibroGen's EBITDA is 1.6.

Sales Growth

FibroGen's sales growth is 5.3% for the present quarter and 16.4% for the next.

More news about FibroGen (FGEN).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 2 Jan 2024
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.